ArticleNPJ Parkinson's disease2020
Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease.
Article in NPJ Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Toxic Alpha-Synuclein and the Opening of the Gate: Blood-Brain Barrier Damage and Stepwise Leukocyte Infiltration.Cellular and molecular neurobiology · 2026Review
- Article
- Perioperative Inflammatory Cytokines in Parkinson's Disease.Biomolecules · 2026Observational
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- GATD3A-mediated monocyte homeostasis and compartmentalized erythrocyte alpha-synuclein discriminate early Parkinson's disease from MSA-P.Frontiers in immunology · 2026Article
- Advances in Circulating Biomarkers for Neurodegenerative Diseases, Traumatic Brain Injuries, and Central Nervous System Tumors.Annals of laboratory medicine · 2025Review
- Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson's disease.World journal of psychiatry · 2025Review
- Therapeutic Efficacy of Small Extracellular Vesicles Loaded with ROCK Inhibitor in Parkinson's Disease.Pharmaceutics · 2025Article
- Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025Review
- Downregulation of Gbp2 Attenuates LPS-Induced Inflammation in BV2 Microglia Cells Through Inhibition of STAT1.Journal of inflammation research · 2025Article
- The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity.Frontiers in neuroscience · 2025Article
- Mutated LRRK2 induces a reactive phenotype and alters migration in human iPSC-derived pericyte-like cells.Fluids and barriers of the CNS · 2024Article
- Pressure sensing of lysosomes enables control of TFEB responses in macrophages.Nature cell biology · 2024Article
- Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV.The Journal of infectious diseases · 2024Article
- Fluid biomarkers in cerebral amyloid angiopathy.Frontiers in neuroscience · 2024Review
- Linking evidence for targeted blood biomarkers in post-stroke cognitive impairment and dementia.Frontiers in stroke · 2024Review
- Cytokine activity in Parkinson's disease.Neuronal signaling · 2023Review
- Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease.Molecular neurodegeneration · 2023Article
- Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD.NPJ Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) and multiple system atrophy (MSA) have overlapping symptoms, challenging a correct early diagnosis. Prognostic information is needed to predict disease progression and provide appropriate counseling. Neuroinflammation plays a role in the pathology of both disorders, as shown in genetic and postmortem tissue studies. Monocyte chemoattractant protein 1 (MCP-1) and neuroleukin (NLK) are two inflammatory proteins with potential to serve as biomarkers of the neuroinflammatory process. Here, we aimed to study the biomarker potential of both MCP-1 and NLK protein levels in cerebrospinal fluid (CSF) from a longitudinal cohort study (Radboudumc, Nijmegen, The Netherlands), consisting of PD patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.